Análise de VEGF-C, COX-2 e IL-17A como biomarcadores do carcinoma epidermóide de cabeça e pescoço

• Autor(a) principal: Bastos, Alliny Cristiny da Silva
• Data de Publicação: 2017
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
• Texto Completo: http://repositorio.ufes.br/handle/10/7090
• topic: Head and neck squamous cell carcinoma; Biomarkers; Carcinoma epidermóide de cabeça e pescoço; Biomarcadores; VEGFC; COX-2; IL-17A; Biotecnologia; 61

Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent types of cancers presenting a high mortality rate and morbidity rate for individuals worldwide. Although several studies present possible biomarkers (BM) for HNSCC there is no specific BM established for this disease. The objective of this work was to evaluate the role of VEGF-C, COX-2 and IL-17A as possible BM of HNSCC, since their high expression has been related to a worse prognosis of the disease. A cross-sectional clinical study, approved by the CEP/UFES Ethics Committee n°99.242/2012, was performed. Biological samples and clinical-pathological data from 124 patients with HNSCC and 29 healthy individuals were collected. The detection of VEGF-C mRNA and COX-2 expression was performed by qPCR trials on tumor tissues and normal tissue samples. The evaluation of VEGFC and COX2 protein expression was performed with serum from both HNSCC patients and a control group by Western blotting. The level of IL-17A (pg/ml) was measured by flow cytometry. Increased relative expression of VEGF-C mRNA in tumor tissue was observed in patients with lymph node metastasis (p=0,027) compared to without lymph node metastasis (p=0,043) and normal tissue samples (p=0,031);Variation of VEGF-C expression in serum of patients in advanced stages of the disease (III/IV) was observed (p=0,01) in comparison with patients in initial stages (I/II) (p = 0,03) and also the control group (p=0,003). COX-2 did not present a significant difference in any of the parameters of the biological samples analyzed. The level of IL-17A was higher in the serum samples from patients in the initial stages of HNSCC (I/II) (p=0,03), in smokers with the disease (p=0,04) and in those without regional lymph node metastases(p=0,04) when compared to the control group. VEGF-C and IL-17A were shown to be potential biomarker of HNSCC in serum samples, being a less invasive and more feasible way to evaluate the patient's condition, whereas for COX-2 new approaches are necessary to evaluate its role in HNSCC.